Propanc Health Group Corp (OTCMKTS:PPCH) released update on current activities and latest achievements. The company reported that animal efficacy trials in numerous tumor cell lines are in progress for PRP with Propanc’s research associate, vivoPharm, in Hershey, PA. These trials are assessing the optimization of the PRP therapy, which are anticipated to even further advance PRP’s anti-tumor impact against the previous pilot trials. The human xenograft orthotopic models will be utilized to support forthcoming regulatory agency meetings and licensing talks.
The update
Propanc stated that pharmacokinetic trials are ongoing in order to produce vital information pertaining to the metabolism of two proenzymes used in the PRP formulation. The data generated will offer significant data related to dosing of proenzymes and thus optimizing the treatment plan for PRP drug in future human trials.
Another animal efficacy trial performed at vivoPharm has integrated a mouse tumor moved in immunocompetent mice. Tissue and blood samples harvested from this trial are presently being arranged to be forward to Adaptive Biotechnologies to exemplify the immune response compared to PRP treated and untreated mice.
Regulatory preparations
Propanc Health Group Corp (OTCMKTS:PPCH) reported that preparations are underway for regulatory agency meetings planned in 2016. The management intends to meet the US Food and Drug Administration, European Medicines Agency and BfArM. These planned advice meetings will provide a platform to discuss major activities designed for the future advancement of PRP, including animal safety and toxicology trials and the planned clinical pathway for human trials in Phase I and II. The company has obtained financing to advance with the planned preclinical animal trials.
In last trading session, the stock price of Propanc declined more than 8% to close the trading session at $0.0459. The decline came at a share volume of 7.56 million compared to average share volume of 4.76 million. After the recent drop, the market cap stands at $16.37 million.
